Skip to main content

Drug Interactions between belumosudil and Tums Chewy Bites with Gas Relief (Lemon & Strawberry)

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

calcium carbonate belumosudil

Applies to: Tums Chewy Bites with Gas Relief (Lemon & Strawberry) (calcium carbonate / simethicone) and belumosudil

MONITOR: Coadministration with gastric acid-reducing agents other than proton pump inhibitors (PPIs) may reduce the oral bioavailability of belumosudil. The mechanism of interaction has not been established. Concomitant use of the PPI rabeprazole decreased belumosudil peak plasma concentration (Cmax) and systemic exposure (AUC) by 87% and 80%, respectively, while coadministration of omeprazole decreased belumosudil Cmax and AUC by 68% and 47%, respectively, in healthy subjects. Data for other gastric acid-reducing agents are not available.

MANAGEMENT: The potential for diminished pharmacologic effects of belumosudil should be considered during coadministration with gastric acid-reducing agents other than PPIs. Other authorities recommend having a dosing interval of at least 12 hours between the latter and belumosudil (GB).

References (2)
  1. (2024) "Product Information. Rezurock (belumosudil)." Sanofi
  2. (2024) "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals, 11/2023

Drug and food interactions

Moderate

calcium carbonate food

Applies to: Tums Chewy Bites with Gas Relief (Lemon & Strawberry) (calcium carbonate / simethicone)

ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.

MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.

References (6)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  3. Cerner Multum, Inc. "Australian Product Information."
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  5. Mangels AR (2014) "Bone nutrients for vegetarians." Am J Clin Nutr, 100, epub
  6. Davies NT (1979) "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc, 38, p. 121-8
Moderate

belumosudil food

Applies to: belumosudil

ADJUST DOSING INTERVAL: Administration with food increases the oral bioavailability of belumosudil. The mechanism has not been described. Administration of belumosudil (200 mg single oral dose) in healthy subjects, with a fatty and calorie-rich meal (approximately half of the calories were contained in the fat) increased the mean belumosudil peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 120% and 100%, respectively, compared to administration under fasting conditions. The time to reach peak concentration (Tmax) was delayed by 30 minutes. Administration of oral belumosudil 200 mg once daily with food in patients with chronic graft-versus-host disease (chronic GVHD) lead to steady-state concentrations of the drug with an accumulation ration of 1.4.

MANAGEMENT: To ensure maximal oral absorption, belumosudil should be administered with a meal, every day at the same time.

References (2)
  1. (2024) "Product Information. Rezurock (belumosudil)." Sanofi
  2. (2024) "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals, 11/2023

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer